Introduction
Lactoferrin also has antibacterial (Ellison, 1994; Miehlke et al., 1996) , antifungal (Kirkpatrick et al., 1971) and antiviral properties (Grover et al., 1997; Marchetti et al., 1998) , which are even directed against HIV-1 (McNeely et al., 1995) . It is interesting to note that the antiviral properties of both lysozyme and lactoferrin are evident at doses usually much higher than those normally present in serum and in most body fluids (with the exception of tears and colostrum, respectively).
In order to verify the possibility of inhibiting herpesvirus infections by both lysozyme and lactoferrin at physiological doses, the combination of these drugs with a natural antiviral compound particularly efficient against herpesviruses, namely glycyrrhizic acid, was assessed (Pompei et al., 1983; Dargan & Subak-Sharpe, 1992; Utsunomiya et al., 1997) . It was found that lactoferrin and, to a lesser extent, lysozyme, were able to significantly enhance the anti-herpetic activity of glycyrrhizic acid, even at concentrations contained in some body secretions.
Materials and Methods

Compounds
Glycyrrhizic acid ammonium salt (GLA) was purchased from Fluka (Bucks); human and bovine lactoferrin (LAC), human, turkey and chicken lysozyme (LYS) were obtained from Sigma-Aldrich. The drugs were dissolved into the culture media immediately before the assays and then sterilized by filtration.
Cells and viruses
In all of the experiments, the Vero cell line was used (ICNFlow), which was cultured in Dulbecco's modified Eagles medium (DMEM), containing foetal calf serum (FS, from Gibco). The in vitro assays on the cell lines were always performed in a 5% CO 2 incubator at 37°C. Herpes simplex virus types 1 and and 2 (HSV-1 and HSV-2) were donated by NIH (Bethesda, Md., USA). HSV-1 was produced in stocks containing ~2×10 7 plaque forming units (pfu) per ml and was kept at -80°C, ready for use.
Cytotoxic activity assays
The Vero cells were inoculated in 6-well plates each containing 9×10 4 cells and incubated in DMEM with 6% FS for 24 h at 37°C and with 5% of CO 2 . After 24 h of culture, the medium was changed and a new medium containing decreasing doses of the substances under study was added. After 5 days the cells were trypsinized and counted in a Neubauer chamber under a light microscope. All the tests were done in triplicate. The minimum 50% toxic dose (MTD 50 ) was defined as the drug concentration that decreased cell multiplication by 50% with respect to the control.
Antiviral activity test
A 'one-step infection method' was employed to evaluate the viral inhibition in the cell cultures. In brief, Vero cell monolayers were infected with HSV-1 at a multiplicity of infection (m.o.i.) of 1-2 infectious units/cell in 24-well plates. After infection, serial dilutions of the drugs were added in some plates. The viruses were grown for about 24 h and then they were recovered from the cells by two cycles of freezing and thawing. The virus titre was determined by the viral plaque formation technique under agar-solidified DMEM. The experiments were done in triplicate and the 50% inhibiting dose (ID 50 ) was determined.
Virucidal activity
A suspension of virus containing about 10 6 pfu/ml was incubated for 1 h at 37°C in the presence of increasing doses of the drugs. Then the virus titre was detected in Vero cell monolayers.
Tests on synergistic activity
The antiviral activity of each compound was evaluated either alone or in combination with another compound. In each experiment one drug was used at a dose lower than the ID 50 and the other compound was employed at seven decreasing doses. The results were used for the calculation of the fractional inhibitory concentration (FIC) index, which represents the mathematical elaboration of the data on the antiviral activity of each compound considered alone and in association. The FIC index was calculated by the (Krogstad & Moellering, 1990; Ishii et al., 1993) .
FIC index values lower than 0.5 detect a significant synergistic activity; values from 0.5 to 0.9 suggest a mild synergism; a value of 1.0 shows an additive result; values higher than 1.0 indicate an antagonistic behaviour between the two compounds (Berembaum, 1978; Kirsi et al., 1984; Hasobe et al., 1986) .
The results were also used for obtaining a diagram, where the concentrations of two drugs and the relative viral inhibiting potencies, could be visualized at the same time. In addition, for the characterization of drug-to-drug interaction, a three-dimensional analytical method was used according to the system described by Prichard et al. (1993) . This experimental design was used to identify the regions at which significant drug interactions occurred. If the interactions were merely additive, the resulting surface would appear as a horizontal plane at 0% inhibition above the calculated additive surface. Any peaks above this plane would be indicative of synergy. Similarly, any depression below the plane would indicate antagonism.
Results
Cytotoxic and antiviral activity
Cytotoxic, antiviral and virucidal activities of the compounds tested are reported in Table 1 . Bovine LAC resulted as exerting a low toxicity at high doses (MTD 50 =2333±577 µg/ml) and the antiviral effect was still evident at about 250 µg/ml. No direct virucidal activity was observed at non-cytotoxic doses. With human LAC almost overlapping results were obtained. Chicken, turkey and human LYS showed a dose-dependent antiviral effect, with an ID 50 between 467 and 500 µg/ml and a cell toxicity not detectable at concentrations up to 6000 µg/ml (the compounds were poorly soluble at higher concentrations). GLA presented a MTD 50 of 6667±577 µg/ml and an ID 50 of 740±125 µg/ml; the virucidal concentration of GLA resulted of 833±289 µg/ml on HSV-1. Since almost overlapping results were obtained with the substances derived from different animals or man, all the experiments of drug combinations were performed with bovine LAC and chicken LYS, which are the proteins usually employed in most anti-viral tests (Harmsen et al., 1995; Marchetti et al., 1998) . Table 2 shows the results of the antiviral activity of the three compounds tested in combination. The association of GLA and LAC leads to a marked decrease of the ID 50 of GLA (from a mean of 740 to a mean of 15 µg/ml) and also of the ID 50 of LAC (from a mean of 252 to a mean of 15 µg/ml). With the combined use of these two drugs, no enhancement of cell toxicity was observed, as compared to when the compounds were used alone (data not shown). The potentiating activity of the combination of GLA and LAC against the HSV1 is clearly shown in Figures 1 and 2, as a dose-response draft. In the most effective dose-combination (about 500 µg/ml GLA + 250µg/ml LAC) a virus reduction of more than 1.5 log 10 was obtained (from 5.5×10 6 to 10 5 pfu/ml). The FIC index calculated for the combination was as low as 0.08, which is very significant in detecting a strong synergistic effect (Table 3 ). The three-dimensional representation of Figure 3 gives an immediate visualization of the enhancement of the anti-herpetic activity of GLA by LAC. In fact, it is possible to observe a synergistic antiviral action that peaks up to 35%, using the dissimilar-site additivity equation of Prichard et al. (1993) . For example, the combination of 500 µg of GLA and 250 µg/ml of LAC induces a 35% enhancement of the antiviral activity, in addition to that expected if the two substances have a simple additive effect. In no case did a combination of these two drugs show an antagonistic activity.
Antiviral effect of drugs in combination
Glycyrrhizic acid and lysozyme. Table 2 reports the values obtained for the association of GLA and LYS. The ID 50 of GLA decreased from 740±125 to 310±66 µg/ml and the ID 50 of LYS from 497±165 to 62±32. Figure 4a reports a dose-response diagram of the association of GLA and LYS. It allows the evaluation of the synergistic activity of some doses of the two drugs. Concentrations of GLA of 500 µg/ml in association with LYS at doses between 250 and 500 µg/ml determine an enhancement of the antiviral action of about 18% (data not shown). The FIC index calculated for the association GLA+LYS resulted equal to 0.54, which represents an value indicative of low-grade synergistic activity (Table 3) .
Combination of lysozyme and lactoferrin. In this association, as indicated in Table 2 , the ID 50 value of LYS decreases from a mean of around 500 to a mean of 125 µg/ml. With regard to LAC, the ID 50 value decreased from a mean of around 250 to a mean of 62 µg/ml. The diagram in Figure  4b shows a low significant synergistic effect between the two substances, with a FIC index of 0.50 (Table 3) .
Discussion
Lysozyme, lactoferrin and glycyrrhizic acid are natural substances whose antiviral activity has been widely demonstrated by several studies, although their mechanisms of action are quite aspecific and still remain unclarified (Cisani et al., 1984; Cisani et al., 1989; Grover et al., 1997; Marchetti et al., 1998; Pompei et al., 1979; Utsunomiya et G Lampis et al. 4 ©2001 International Medical Press , 1997) . The only accepted property of these compounds on viruses is the low specificity of action and the quite high doses needed to exert a protective in vitro effect. Consequently, their use has been generally suggested for the treatment of topic herpetic lesions in the mouth, genitalia and eyes (Cavicchini, 1984) . The finding that a synergistic effect can be obtained by the combination of these compounds is very interesting since it allows us to consider the possibility of reaching more effective viral suppression at the same doses used for the single drugs, or, more importantly, it allows an antiviral effect to be obtained at doses much lower than those needed for the single compounds, with the opportunity of developing an effective systemic treatment of some viral infections.
LAC and LYS are physiological substances that are present in low amounts in most bodily secretions. They reach antiviral doses only in some particular organs, such as the eyes for LYS and colostrum for LAC. The concentrations usually found in serum or in other organic fluids (between 1 and 200 µg/ml) have some antibacterial activity and can be considered as one of the first non-specific protection barriers against microbial invasion in infants, but they show little or no activity against most human pathogenic viruses.
The findings about the successful combination of GLA and LAC were particularly interesting, since the FIC index resulted strongly indicative of a marked anti-herpetic effect improvement of the single drugs. In this case the potentiation of the antiviral activity is clear and significant, with a virus reduction which is, for some concentrations of the two drugs, higher than 1.5 log 10 , in comparison to the drugs used alone.
GLA and LAC have quite a different action on viruses and cells. GLA also acts on intracellular viruses, mainly on viral morphogenesis, where it alters the normal process of synthesis of viral glycoproteins, leading to the production of defective and non-infectious virions, which are unable to normally attach and penetrate into the cells, thus lowering the viral capability to cause a progressive disease (Dargan & Subak-Sharpe, 1992; Pompei et al., 1979) . In addition, GLA has some direct viruscidal activity on infectious HSV-1 virions. These properties make GLA efficient in suppressing viral production even when it is added to the cells in the late steps of viral reproduction, whilst LAC is mainly active on the early steps of the viral infection, which precede virus uncoating and nucleic acid duplication. LAC at concentrations close to those present in many body secretions, such as in saliva and seminal fluid, but also in plasma under certain special conditions, is able to enhance the antiviral activity of GLA. In addition, during some bacterial infections, concentrations of LAC can increase up to 200 µg/ml (Lash et al., 1983) , which are highly inhibitory against HSV-1 in combination with GLA.
LYS was less efficient in enhancing the antiviral activity of GLA. This fact is not surprising, since at some concentrations LYS formed insoluble compounds with GLA, which rendered both compounds inactive. However, in a special range of concentrations, both GLA and LYS were able to potentiate each other in their anti-herpetic activity. This potentiation was evident, also in this case, at doses of LYS that are present in saliva and in some bronchial and intestinal secretions. LAC and LYS did not show a significant synergistic activity against herpesviruses; this fact is understandable, since the two compounds are quite similar in their action: they mainly exert their function on extracellular viruses by an aspecific interaction with surface negatively charged molecules, which impairs the process of virus attachment and entry into the cells, and also, at least partly, the capacity of viruses to spread from infected to non-infected cells (Cisani et al., 1989) . In conclusion, some natural physiological proteins, namely lactoferrin and, to a lower extent, lysozyme, have been shown to be able to increase the anti-herpetic activity of another natural non-toxic drug such as GLA, within a range of concentrations which have been demonstrated as possessing a pharmacological value. These findings can lead not only to the proposal of a therapeutical formulation of the former drugs in combination, but also to the design of a preventive treatment against herpesvirus infections in high risk patients, who could benefit from the enhancement of their natural aspecific antimicrobial defences by the use of pharmacological doses of GLA. Finally, the observation that LAC and LYS potentiate the antiviral effect of GLA could explain the finding that lower concentrations of the latter compound were needed in in vivo experiments than those required for exerting a significant antiviral activity in in vitro systems (Utsunomiya et al., 1997) . 
